Answers are grounded in this paper and cite their sources.
Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for treating renal anemia yet have failed clinical testing for inflammatory bowel disease because of a lack of efficacy. Here we used a multimodel multimodal generative artificial intelligence platform to design an orally gut-restricted selective PHD1 and PHD2 inhibitor that exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models. Generative artificial intelligence is used to design an effective treatment for inflammatory bowel disease in preclinical models.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: